Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?

Paola Ulivi

Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy; paola.ulivi@irst.emr.it; Tel.: +39-0543-739277

Academic Editor: William Chi-shing Cho
Received: 23 May 2016; Accepted: 15 July 2016; Published: 22 July 2016

Abstract: The induction of resistance mechanisms represents an important problem for the targeted therapy of patients with non-small-cell lung cancer (NSCLC). The best-known resistance mechanism induced during treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is \textit{EGFR} T790M mutation for which specific drugs are have been developed. However, other molecular alterations have also been reported as induced resistance mechanisms to EGFR-TKIs. Similarly, there is growing evidence of acquired resistance mechanisms to anaplastic lymphoma kinase (ALK)-TKI treatment. A better understanding of these acquired resistance mechanisms is essential in clinical practice as patients could be treated with specific drugs that are active against the induced alterations. The use of free circulating tumor nucleic acids or circulating tumor cells (CTCs) enables resistance mechanisms to be characterized in a non-invasive manner and reduces the need for tumor re-biopsy. This review discusses the main resistance mechanisms to TKIs and provides a comprehensive overview of innovative strategies to evaluate known resistance mechanisms in free circulating nucleic acids or CTCs and potential future orientations for these non-invasive approaches.

Keywords: lung cancer; TKI-resistance; liquid biopsy; EGFR; EML4–ALK

1. Introduction

Tyrosine kinase inhibitors (TKIs) represent a group of anticancer agents showing important results in the treatment of patients with non-small-cell lung cancer (NSCLC) harboring specific molecular alterations. In particular, epidermal growth factor receptor (EGFR)-TKIs are capable of improving response and prolonging progression-free survival (PFS) in selected patients harboring specific \textit{EGFR} mutations occurring principally at exons 18, 19 and 21 [1–4]. Gefitinib [2], erlotinib [3] and, more recently, afatinib [5], are the only three TKIs approved for the first-line treatment of \textit{EGFR}-mutated advanced NSCLC, which represents about 10%–15% of all NSCLC. Alterations of the anaplastic lymphoma kinase (ALK), present in about 5% of NSCLC, define another subgroup of tumors that are highly responsive to ALK-TKIs, such as crizotinib [6]. The objective response rate (ORR) of these drugs in selected patients is about 75%–80% and randomized clinical trials have also reported improved PFS [1–3,6]. However, the long-term effectiveness of these therapies is usually limited by the development of resistance mechanisms that consequently lead to disease progression within one year of starting treatment [1–3,7,8]. The characterization and identification of such mechanisms is an important field of research and new drugs capable of overcoming resistance are beginning to emerge. Furthermore, as recurrent NSCLC lesions can only be characterized by performing bronchoscopy, the development of non invasive strategies for this purpose would constitute an important step forward in this setting. Free circulating tumor nucleic acids or circulating tumor cells (CTCs) represent one such strategy.
2. Acquired Resistance Mechanisms to Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) and Possible Strategies for Their Inhibition

2.1. Gatekeeper EGFR T790M Mutation

The mechanisms of resistance induced by EGFR-TKI treatment in EGFR-mutated NSCLC patients have been widely investigated. The main molecular alteration induced in over 50% of patients who become resistant to TKI is the threonine-to-methionine substitution within the gatekeeper residue at amino acid position 790 (T790M) of the EGFR gene [9]. Threonine 790 has been designated as a “gatekeeper” residue and is important for regulating inhibitor specificity in the adenosine triphosphate (ATP) binding pocket. The T790M mutation enhances affinity of the ATP binding pocket for ATP, thus successfully competing with TKIs and ultimately conferring resistance. Tumors carrying EGFR mutation are usually sensitive to competitive inhibitors as such mutations reduce the receptor’s affinity for ATP. The onset of T790M re-established the ATP affinity of the kinase back to wild-type levels, restoring ATP as the favored substrate instead of the TKI [10]. Tumors developing this alteration are usually more indolent [11] and patients tend to have longer post-progression survival (PPS) than those without the mutation [12]. Given that tumors harboring a T790M mutation are still addicted to the EGFR signaling pathway, new drugs that irreversibly block EGFR, e.g., second-generation TKIs, may be capable of increasing the potency of EGFR-TK inhibition. One such inhibitor, the second-generation EGFR-TKI afatinib (BIBW-2992), is capable of selectively blocking both wild-type and mutant forms of ErbB family receptors (EGFR, ErbB2, ErbB3 and ErbB4) [10]. However, despite initially promising results reported in some clinical studies [13,14], the potential of afatinib appears to be somewhat weakened due to toxicity and insufficient blood concentrations that fail to overcome the EGFR T790M mutation [15]. Thus, several third-generation EGFR-TKIs selectively targeting the mutant EGFR (in particular, the T790M mutation) but with minimal potency towards the wild-type receptor have emerged in quick succession [16,17]. The pyrimidine compound AZD9291, a potent, irreversible EGFR inhibitor that targets via covalent binding the cysteine-797 residue in the ATP binding site [17,18], has showed strong activity in different in vitro models carrying EGFR mutation with or without T790M [17]. This agent was studied in a phase I trial in patients with EGFR-mutant advanced NSCLC who progressed during EGFR-TKIs treatment. Median PFS in patients with or without a confirmed T790M was 9.6 months (95% confidence interval (CI), 8.3 months–not reached) and 2.8 months (95% CI, 2.1–4.3 months), respectively [19]. Given the proven activity and favorable toxicity profile of AZD9291 in patients with EGFR-mutant NSCLC who progress on EGFR-TKIs, approval by regulatory agencies is expected in the near future. However, other resistance mechanisms to AZD9291 have also been reported [20].

2.2. Mesenchimal–Epithelial Transition (MET) Amplification

The mesenchymal–epithelial transition (MET) receptor, a transmembrane tyrosine kinase encoded by the proto-oncogene MET, has been acknowledged as one of the main causes of acquired resistance to gefitinib or erlotinib in NSCLC. Once bound to its ligand (hepatocyte growth factor), MET tyrosine kinase phosphorylation is induced, triggering the activation of the downstream PI3K/AKT/mTOR pathway, one of the key signaling pathways for cell proliferation, survival and anti-apoptosis [21]. About 20% of tumors with EGFR-TKI acquired resistance have been shown to possess MET gene amplification [21,22] and some strategies have been studied to inhibit MET activity. Tivantinib is a non-ATP-competitive small molecule MET inhibitor that showed promising results in the MARQUEE trial [23]. However, the efficacy of the drug would not seem to be related to MET expression [24]. Other strategies include the use of monoclonal anti-MET antibodies. Onartuzumab (MetMAb), a newly developed humanized monoclonal antibody targeting MET, prevents hepatocyte growth factor from binding to MET, inhibiting the activation of its downstream transducers and effectors [25]. However, a recent phase III trial failed to show any benefit from the drug plus erlotinib compared to erlotinib only in MET-positive patients [26].
2.3. Insulin-Like Growth Factor-1 Receptor (IGF-1R)

Higher insulin-like growth factor-1 receptor (IGF-1R) expression levels have been detected in patients with acquired gefitinib resistance than in those who are sensitive to the drug [27]. The mechanisms through which IGF-1R is activated are still unknown. The activation of this receptor induces survival signals such as PI3K/AKT and MAPK to activate the mammalian target of rapamycin (mTOR), inducing the synthesis of EGFR and anti-apoptotic survivin proteins [28]. The concomitant treatment of IGF-1R inhibitors such as α-IR3, AG1024 or R1507 with EGFR-TKIs may enhance TKI-induced growth inhibition and apoptosis, representing a potential strategy for overcoming primary resistance to EGFR-TKIs in NSCLC [29,30].

2.4. Human Epidermal Growth Factor Receptor (HER) 2 Mutations

Human Epidermal Growth Factor Receptor 2 (HER2) mutations are present in about 2% of lung adenocarcinomas and induce the constitutive activation of HER2 protein, leading to the activation of EGFR through heterodimerization [31]. This mechanism may lead to EGFR activation, independently of the action of EGFR-TKIs [31,32]. Moreover, EGFR-TKI resistance can be mediated by HER2 gene amplification or protein overexpression [33], providing a rationale for the use of HER2-targeted agents such as lapatinib, trastuzumab or dacomitinib in combination with EGFR-TKIs to treat NSCLC patients who develop HER2 alterations [34].

2.5. Activation of Alternative Proliferation Pathways

The PI3K/AKT/mTOR signaling pathway, which is downstream to the activation of tyrosine kinase receptors (EGFR, MET, HER2, HER3), plays an important role in promoting the proliferation, survival and drug resistance of cancer cells [35]. Some studies have also reported that the involvement of mTOR pathway in specific diseases causes defects in translation and that stimulation of this pathway would seem to have therapeutic potential [36–38]. Although there is little clinical data on the prevalence of PI3K/AKT/mTOR pathway-induced EGFR-TKI resistance, the involvement of this pathway in induced EGFR-TKI resistance has been repeatedly confirmed by preclinical research [39,40]. However, PIK3CA mutations have been identified in a small percentage of EGFR-mutant lung cancers acquiring resistance to EGFR-TKIs [41]. Although the combination of EGFR-TKIs and PIK3CA inhibitors is a potential challenge because of overlapping toxicities, it is currently being evaluated in a number of clinical trials [42].

2.6. Phenotypic Changes

The phenotypic transformation of NSCLC histology into small cell lung cancer (SCLC) was demonstrated for the first time by Sequist et al. [41] who used immunohistochemical staining for synaptophysin in post-resistance biopsy specimens to confirm positivity for the SCLC phenotype [41]. Molecular analysis also showed that the EGFR mutation was maintained in the newly-developed SCLCs. It can be hypothesized that SCLC cells originate from minor pre-existing cells under the selective pressure of EGFR-TKIs, transdifferentiate from adenocarcinoma cells, or arise from multipotent stem cells [43].

Another documented phenotypic change responsible for acquired resistance to TKIs is the epithelial to mesenchymal transition (EMT). Typical molecular events characterizing this phenomenon are the loss of epithelial cell junction proteins such as E-cadherin and the acquisition of mesenchymal markers such as vimentin or fibronectin [44]. It has been demonstrated that EMT accounts for about 5% of all cases of EGFR-TKI resistance [41]. However, NSCLC cells with a lower degree of EMT but no EGFR-mutations have also shown sensitivity to EGFR-TKIs in both in vitro and xenograft models [45,46].
3. Acquired Resistance Mechanisms to Anaplastic Lymphoma Kinase (ALK)-TKIs

3.1. ALK-Dependent Mechanisms

3.1.1. Secondary Mutations at the ALK Gene

The first major “gatekeeper” mutation identified in the TK domain of echinoderm microtubule associated protein like 4 (EML4)-ALK was described in an ALK-positive patient who progressed after 5 months’ treatment with crizotinib. Analysis of the patient’s pleural fluid revealed two non-overlapping mutations in the ALK kinase domain (L1196M and C1156Y), each independently conferring crizotinib resistance in vitro [47]. The substitution of leucine for a methionine at position 1196 (L1196M) induced a mutant bulky amino-acid side chain in the ATP-binding pocket of the receptor, interfering with the binding of crizotinib to its receptor. Subsequent analyses performed on tumor tissue acquiring resistance to crizotinib revealed other “non-gatekeeper” second-site ALK mutations distributed throughout the kinase domain [48–50]. These gatekeeper mutations inhibit binding of crizotinib to the kinase domain of the ALK receptor, leading to its ineffectiveness. However, not all secondary ALK mutations have the same impact on the efficacy of anti-ALK agents. The presence of G1202R ALK mutation confers high-level resistance not only to crizotinib but also to next-generation ALK inhibitors, whereas the L1196M mutation may still be sensitive to newer ALK inhibitors such as CH5424802 [51].

3.1.2. ALK Amplification

An increase in ALK gene fusion copy number was recently implicated as a cause of crizotinib resistance. This phenomenon was initially observed in cell line models in which the amplification of wild-type EML4–ALK was sufficient to induce crizotinib resistance, and later confirmed in resistant clinical biopsy specimens [52,53].

3.2. ALK-Independent Mechanisms

The activation of ALK-independent signaling pathways contributes to acquired resistance to ALK-TKIs in up to 20% of ALK-positive NSCLCs [54]. These mechanisms include activation of EGFR, HSP90, PI3K/AKT/mTOR pathways, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations and KIT amplifications. With regard to EGFR, increased phosphorylation of the receptor and upregulation of EGFR ligands, e.g., EGF and amphiregulin, have been observed [55,56]. It has also been hypothesized that activation of autophagy through the AKT/mTOR signaling pathway may contribute to drug resistance and that the inhibition of autophagy with chloroquin may restore sensitivity to crizotinib in ALK-resistant cell lines [57]. Finally, KRAS mutations and KIT gene amplification have been identified in ALK-positive patients during treatment with crizotinib, suggesting that these signaling pathways may also contribute to the develop of resistance [50].

4. Use of Non-Invasive Methods for the Detection of Resistance Mechanisms to TKIs

The identification of molecular alterations responsible for acquired TKI resistance is important from a clinical point of view as subsequent targeted treatment can then be given (Figure 1). At present, such alterations can only be characterized by biopsy of the recurrent lesion, an invasive procedure that is not without risk for patients. Moreover, as tumors are heterogeneous, a single biopsy sample taken from a specific area of the lesion may not be fully representative of the tumor as mutations may be present in some areas but not in others. The selective pressure induced by treatment with EGFR-TKI can also contribute to increasing heterogeneity. An alternative could be to identify the specific alteration by non-invasive methodologies, e.g., free circulating tumor DNA (fctDNA) or CTCs. Although these non-invasive approaches may not be as sensitive as tumor tissue analysis, they nevertheless offer important advantages. First, fctDNA and CTCs may be more representative of the overall tumor area as they can be released from any part of the tumor mass, making it easier to identify mutations present. These methods also enable patients to be monitored during treatment, leading to the
timely identification of the onset of treatment resistance [58]. Numerous studies have been performed to verify the potential of non-invasive strategies to identify induced resistance mechanisms to TKIs.

**Figure 1.** Schematic representation of the possible impact of liquid biopsy analysis during the course of treatment in (A) an epidermal growth factor receptor (EGFR)-mutated patient treated with an EGFR-tyrosine kinase inhibitors (TKIs) and (B) a patient with echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4–ALK) translocation treated with an ALK-TKI. NSCLC, non-small-cell lung cancer; MET, mesenchymal–epithelial transition; HER2, human epidermal growth factor receptor 2.

4.1. EGFR Mutations

A great deal of research has been performed to identify EGFR T790M mutations and to monitor EGFR-sensitive mutations in fctDNA or CTCs during the course of TKI treatment [59–69] (Table 1).
Table 1. Literature data on T790M identification in free circulating tumor DNA (fctDNA) during tyrosine kinase inhibitors (TKI) treatment.

| Author (Reference)         | Year | Methodology                          | No. of Patients * | T790M Detected in Plasma (%) | Concordance between T790M in Plasma/CTCs and Tumor Re-Biopsy (%) | T790M Identified Prior to Clinical Disease Progression |
|----------------------------|------|--------------------------------------|-------------------|-------------------------------|---------------------------------------------------------------------|-----------------------------------------------------|
| Lee et al. [59]            | 2016 | ddPCR                                | 79                | 29                            | NE                                                                  | Yes                                                 |
| Sueoka-Aragane et al. [60] | 2016 | MBP-QP                               | 87                | 40                            | 50                                                                  | Yes                                                 |
| Seki et al. [61]           | 2016 | Picoliter ddPCR                      | 35                | 44                            | 80                                                                  | NE                                                  |
| Ishii et al. [62]          | 2015 | ddPCR                                | 18                | 56                            | 83                                                                  | NE                                                  |
| Sorensen et al. [63]       | 2014 | Cobas EGFR blood test                | 23                | 39                            | NE                                                                  | Yes                                                 |
| Wang et al. [64]           | 2016 | DHPLC                                | 135               | 43                            | NE                                                                  | NE                                                  |
| Zheng et al. [65]          | 2016 | ddPCR                                | 117               | 47                            | NE                                                                  | Yes                                                 |
| Sakai et al. [66]          | 2013 | SABER-Sequenom MassARRAY             | 75                | 28                            | NE                                                                  | NE                                                  |
|                            |      | CTC-enriched PCR method              |                   |                               | 57/74 †                                                             | NE                                                  |
| Sunderasan et al. [67]     | 2016 | fctDNA-Cobas EGFR mut test           | 32                | 50                            | 60/61 †                                                             | NE                                                  |
|                            |      | CTCs and fctDNA together             | 23                | 100                           | 65/69 †                                                             | NE                                                  |
| Marcq et al. [68]          | 2014 | ARMS                                 | 2                 | 50                            | NE                                                                  | NE                                                  |
| Del Re et al. [69]         | 2016 | ddPCR                                | 33                | 33                            | 62.5                                                                | NE                                                  |

* Number of epidermal growth factor receptor (EGFR)-mutated patients treated with TKIs and monitored for T790M mutation; † percentages refer to multiple re-biopsies; NE, not evaluable; CTCs, circulating tumor cells; ddPCR, droplet digital PCR; MBP-QP, mutation-biased polymerase chain reaction (PCR) quenching probe; DHPLC, denaturing high performance liquid chromatography; ARMS, amplification refractory mutation system.
A recently published study used droplet digital PCR (ddPCR) to analyze plasma from 79 NSCLC patients treated with TKIs and monitored every 8 weeks until progression [59]. The clinical sensitivity of EGFR mutation detection in plasma, assessed in 58 patients for whom baseline samples were available, was 74%, with 100% specificity. Baseline EGFR mutation positivity in 40 patients decreased to an undetectable mutation level during treatment. The authors also found that PFS and overall survival (OS) were longer in patients with undetectable EGFR mutations (10.1 and 23.7 months, respectively) than in those with detectable mutations (6.3 and 11.2 months, \( p = 0.006 \) and \( p = 0.001 \), respectively). Among the 49 patients with sample availability at progression, 14 (28.6%) had T790M mutations, 8 of which were detected 2–12 months prior to radiological progression and 6 at the time of progression [59]. Another recent study reported that 58/87 EGFR-mutated patients treated with a TKI progressed, 23 (40%) showing T790M mutations in plasma. The mutations were detected over a period ranging from 11 months pre-progression to 9 months post-progression [60]. T790M mutation was more frequent in males, smokers and patients with exon 19 deletion. Moreover, T790M-negative patients who progressed showed a longer OS than T790M-positive patients (median 782 vs. 516 days, respectively) [60]. In contrast, another study performed on 23 patients reported T790M mutations in 39% of cases. The T790M-positive group showed a time-to-progression of 341 days compared to 152 days for those without T790M alterations. In the same study, T790M mutation was detectable up to 344 days before clinically evident disease progression [62]. In another study, an increase in T790M alteration during TKI treatment was associated with a longer PFS and OS than a decrease in the mutation rate [64].

Other recent results obtained on 117 EGFR-mutated NSCLC patients acquiring resistance to TKIs revealed that T790M was detectable in 47% of patients, almost half of whom showed the mutation a median of 2.2 months before clinically evident progressive disease. Moreover, T790M-positive patients had a significantly shorter OS (26.9 months) than those with no T790M mutation (not reached, \( p = 0.05 \)) [65]. However, another study did not report any difference in PFS between T790M-positive and -negative patients [66].

Overall, conflicting results emerge from the studies published on the prognostic role of T790M mutations, some correlating them with a poorer prognosis [60,65], some with a more favorable prognosis [63], and others reporting no difference in survival between T790M-positive and -negative patients [66]. However, studies on tissue re-biopsy would seem to confirm that patients acquiring the T790M mutation have a better outcome than those who do not develop this resistance mechanism [11,12]. Moreover, results from an in vitro study showed that T790M-positive cell lines had different growth kinetics than those without the mutation, i.e., a slower proliferation rate and consequently more indolent tumor growth [70].

Recently, Sundaresan et al. compared tumor biopsy, fctDNA and CTCs for their potential to identify T790M mutations [67], reporting detection rates of 47%, 50% and 50%, respectively. The authors concluded that, although the combined use of fctDNA and CTCs could effectively increase the rate of T790M identification, the high cost of CTC analysis represents a major limitation to its use in clinical practice.

Other authors have shown that monitoring EGFR mutations may also be useful in patients who develop the T790M mutation during treatment with third-generation TKIs [71,72]. In particular, Thress et al. reported that fctDNA analysis during treatment with AZD9291 permitted tumor molecular characterization and led to the identification of EGFR C797S mutation as an acquired resistance mechanism to the drug [72].

Results from other studies underline the possibility of quantifying EGFR-sensitizing mutations, even after only a few days’ treatment, to predict response to TKIs [73–75]. In the study by Tseng et al. on 62 EGFR-mutant patients treated with TKIs, failure to clear plasma EGFR mutations (evaluated by peptide nucleic acid-zip nucleic acid polymerase chain reaction clamp method) after treatment was found to be an independent predictor of lower disease control rate and shorter PFS and OS [74]. More specifically, Marchetti et al. evaluated 69 EGFR-mutated patients using next generation
sequences (NGS) and PCR-based approaches, observing that a decrease in plasma EGFR mutation during the first few days of treatment was closely correlated with response. In particular, the authors found that mutations began to decrease from the fourth day of treatment onwards and showed an average decrease of 63.5% after 14 days. In rapid responders, a rapid decrease in mutated plasma EGFR DNA was associated with high levels of tumor reduction after a few months, and no T790M mutation was observed in plasma. Conversely, slow responders showed a high frequency of T790M mutations, the authors hypothesizing a greater susceptibility of this group to develop early resistance [73].

4.2. MET Amplification

Relatively few studies have been performed to analyze MET amplification during treatment with TKIs [62,64]. In the study by Wang et al., MET amplification was detected in 19% of patients who progressed during TKIs and developed a T790M mutation. The percentage of MET amplification was higher (32%) in patients who showed a decrease in T790M during treatment than in those with an increase in the mutation (12%) [64]. Conversely, Ishii et al. did not observe MET gene copy number gain in plasma of 18 EGFR-mutated patients with acquired resistance to TKIs [62].

4.3. KRAS Mutations

KRAS mutations would not seem to be involved in creating primary resistance to TKIs in NSCLC [76–78]. However, a recent study evaluating KRAS in fctDNA of 33 EGFR-mutated patients receiving TKIs found that 16 (49%) had a plasma KRAS mutation at codon 12 at progression. Moreover, 12/16 patients had a concomitant EGFR T790M mutation. Further research is warranted to clarify the role of KRAS in this context [79,80].

4.4. ALK Alterations

There is increasing evidence of the potential for detecting ALK rearrangements using non-invasive methods [81–85]. The first study focusing on the identification of EML4–ALK translocation was performed by Ilie et al. who used a method for CTC isolation based on size (isolation by size of epithelial tumor cells, ISET) and then evaluated ALK by fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) methods [81]. All five patients with ALK-positive tumors showed both IHC and FISH ALK positivity in CTCs, demonstrating 100% sensitivity, and no ALK-positive CTCs were found in patients with ALK-negative tumors. Subsequently, Pailler et al. [82] aimed to identify the translocation in CTCs of patients with EML4–ALK-positive NSCLC using a filtration enrichment technique and filter-adapted fluorescent in situ hybridization (FA-FISH) method. All 18 ALK-positive patients tested were positive for ALK-rearranged CTCs, with 100% sensitivity and nearly absolute specificity. Conversely, using the CellSearch methodology, CTCs were found in only 6 (35%) of the 17 samples analyzed. The authors also found that ALK-rearranged CTCs had a homogeneous mesenchymal phenotype, independently of the heterogeneous marker expression observed in the tumor specimens. Moreover, 5 patients receiving crizotinib were monitored for ALK-rearranged CTCs, the authors confirming that quantitative and qualitative analysis of circulating tumor cells was feasible during treatment [82].

Two other recent reports suggested that CTC analysis may be useful in detecting EML4–ALK rearrangement [83,84]. He et al. demonstrated the superiority of the CTC-enrichment method NanoVelcro over the CellSearch methodology, reporting 100% sensitivity of the former in detecting EML4–ALK translocation in 21 ALK-positive patients analyzed. The authors also confirmed that it was possible to monitor patients during the course of treatment [83]. Similarly, another study using the ClearCell FX system to isolate CTCs reported a high concordance of the method in detecting ALK-rearranged CTCs in ALK-positive patients. Patient monitoring during treatment revealed ALK FISH rearrangement suggestive of gene copy number increase in those who progressed [84].

Another recent study by Nilsson et al. showed that the detection of EML4–ALK translocation is feasible in RNA isolated from circulating blood platelets [85]. The authors reported that plasma RNA
translocation was only evaluable in 3 out of 14 EML4–ALK rearranged tumors, indicating a sensitivity of 21% and a specificity of 100%. Conversely, the evaluation of platelet-derived RNA in 34 patients with EML4–ALK translocation showed a sensitivity of 65% and maintained 100% specificity. Moreover, the authors found that the presence of EML4–ALK translocation in platelets was associated with shorter PFS and OS. No differences in terms of response to crizotinib were observed between patients with circulating EML4–ALK positivity or negativity. One patient in whom the translocation was detected in platelets was monitored, the authors reporting that the alteration disappeared during treatment but re-appeared 2 months before radiological progression was documented [85]. This is suggestive of the development of ALK-independent resistance mechanisms.

The identification of EML4–ALK translocation by non-invasive methods seems feasible, with CTCs possibly the best option as morphological characteristics of cells can also be evaluated, providing information that can be correlated with response to therapy. Moreover, CTC analysis appears to be more accurate for translocation detection as it shows absolute sensitivity and specificity and methods such as filter-adapted fluorescent in situ hybridization (FA FISH), NanoVelcro or ClearCell FX would seem to be more efficient than CellSearch. However, further studies are needed to identify the best methods for detecting circulating EML4–ALK and to verify whether the identification of the translocation is useful in monitoring response to crizotinib.

The analysis of ALK alterations in liquid biopsy could also be integrated by the search for ALK mutations recognized as mechanisms of resistance to crizotinib in tumor tissue, e.g., L1196M and C1156Y [47], or for other known mutations distributed throughout the kinase domain [48–50]. The mutations in question are somatic mutations and could thus be evaluated in fctDNA using the same methodologies as those employed for the detection of EGFR T790M alterations. The identification of resistance mechanisms induced during crizotinib treatment would help us to understand whether the tumor has developed ALK-dependent or -independent resistance and could orient the choice of subsequent treatment accordingly.

5. Conclusions and Future Directions

The analysis of EGFR mutations in fctDNA represents a validated methodology that is now ready for use in clinical practice to identify resistance to TKIs (by T790M analysis) or to monitor TKI response after only a few days’ treatment (through the detection of EGFR-sensitizing mutations). The fact of being able to identify somatic point mutations in fctDNA means that all the mutations responsible for creating resistance can be detected and monitored in a non-invasive way. As fctDNA evaluation is a relatively simple, inexpensive and rapid approach, it could easily be implemented in clinical practice. In fact, all the DNA mutations with a proven role in causing TKI resistance can be determined in fctDNA. However, as there are still no drugs available for each single alteration causing TKI resistance, the usefulness of fctDNA in clinical practice is, for the moment, somewhat limited. The analysis of other types of alterations not identifiable in DNA that require RNA isolation is slightly more problematic as free RNA is not as stable as DNA. However, the fact that some studies have shown the feasibility of analyzing EML4–ALK translocation in CTCs [81–84] or in RNA isolated from circulating blood platelets [85] has opened up interesting new avenues of research. The same non-invasive approaches could also potentially be used to search for c-ros oncogene 1 (ROS1) rearrangements. Pending the development of new drugs targeting mutations responsible for resistance, further research is warranted into the evaluation of the prognostic role of fctDNA alterations as potential indicators of TKI response and patient outcome.

In conclusion, despite the acknowledged advantages of using liquid biopsy (it is a non-invasive approach, representative of the heterogeneous nature of the tumor, and can be used to monitor patients during treatment) which facilitate the timely detection of the onset of resistance mechanisms, further efforts are needed to increase the sensitivity of the methodologies to reduce the risk of false-negative results.
Acknowledgments: The author thanks Cristiano Verna for editing the manuscript and Francesco Mazza for his help in preparing the figure.

Conflicts of Interest: The author declares no conflict of interest.

References
1. Maemondo, M.; Inoue, A.; Kobayashi, K.; Sugawara, S.; Oizumi, S.; Isobe, H.; Gemma, A.; Harada, M.; Yoshizawa, H.; Kinoshita, I.; et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N. Engl. J. Med.* 2010, 362, 2380–2388. [CrossRef] [PubMed]
2. Mok, T.S.; Wu, Y.L.; Thongprasert, S.; Yang, C.H.; Chu, D.T.; Saijo, N.; Sunpaweravong, P.; Han, B.; Margono, B.; Ichinose, Y.; et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N. Engl. J. Med.* 2009, 361, 947–957. [CrossRef] [PubMed]
3. Rosell, R.; Carcereny, E.; Gervais, R.; Vergnenegre, A.; Massuti, B.; Felip, E.; Palmero, R.; García-Gomez, R.; Pallares, C.; Sanchez, J.M.; et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. *Lancet Oncol.* 2012, 13, 239–246. [CrossRef]
4. Zhou, C.; Wu, Y.L.; Chen, G.; Feng, J.; Liu, X.Q.; Wang, C.; Zhang, S.; Wang, J.; Zhou, S.; Ren, S.; et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. *Lancet Oncol.* 2011, 12, 735–742. [CrossRef]
5. Yang, J.C.; Wu, Y.L.; Schuler, M.; Sebastian, M.; Popat, S.; Yamamoto, N.; Zhou, C.; Hu, C.P.; O’Byrne, K.; Feng, J.; et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials. *Lancet Oncol.* 2015, 16, 141–151. [CrossRef]
6. Solomon, B.J.; Mok, T.; Kim, D.W.; Wu, Y.L.; Nakagawa, K.; Mekhail, T.; Felip, E.; Cappuzzo, F.; Paolini, J.; Usari, T.; et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N. Engl. J. Med.* 2014, 371, 2167–2177. [CrossRef] [PubMed]
7. Kwak, E.L.; Bang, Y.J.; Camidge, D.R.; Shaw, A.T.; Solomon, B.; Maki, R.G.; Ou, S.H.; Dezube, B.J.; Janne, P.A.; Costa, D.B.; et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N. Engl. J. Med.* 2010, 363, 1693–1703. [CrossRef] [PubMed]
8. Camidge, D.R.; Bang, Y.J.; Kwak, E.L.; Iafrate, A.J.; Varella-Garcia, M.; Fox, S.B.; Riely, G.J.; Solomon, B.; Ou, S.H.; Kim, D.W.; et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. *Lancet Oncol.* 2012, 13, 1011–1019. [CrossRef]
9. Pao, W.; Miller, V.A.; Politi, K.A.; Riely, G.J.; Somwar, R.; Zakowski, M.F.; Kris, M.G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med.* 2005, 2, e73. [CrossRef] [PubMed]
10. Yun, C.H.; Mengwasser, K.E.; Toms, A.V.; Woo, M.S.; Greulich, H.; Wong, K.K.; Meyerson, M.; Eck, M.J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. *Proc. Natl. Acad. Sci. USA* 2008, 105, 2070–2075. [CrossRef] [PubMed]
11. Oxnard, G.R.; Arcila, M.E.; Sima, C.S.; Riely, G.J.; Chmielecki, J.; Kris, M.G.; Pao, W.; Ladanyi, M.; Miller, V.A. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation. *Clin. Cancer Res.* 2011, 17, 1616–1622. [CrossRef] [PubMed]
12. Hata, A.; Katakami, N.; Yoshioka, H.; Takeshita, J.; Tanaka, K.; Nanjo, S.; Fujita, S.; Kaji, R.; Imai, Y.; Monden, K.; et al. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations. *Cancer* 2013, 119, 4325–4332. [CrossRef] [PubMed]
13. Miller, V.A.; Hirsh, V.; Cadranel, J.; Chen, Y.M.; Park, K.; Kim, S.W.; Zhou, C.; Su, W.C.; Wang, M.; Sun, Y.; et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial. *Lancet Oncol.* 2012, 13, 528–538. [CrossRef]
14. Katakami, N.; Atagi, S.; Goto, K.; Hida, T.; Horai, T.; Inoue, A.; Ichinose, Y.; Koboyashi, K.; Takeda, K.; Kiura, K.; et al. LUX-Lung 4: A phase ii trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J. Clin. Oncol. 2013, 31, 3335–3424. [CrossRef] [PubMed]

15. Lee, H.J.; Schaefer, G.; Heffron, T.P.; Shao, L.; Ye, X.; Sideris, S.; Malek, S.; Chan, E.; Merchant, M.; La, H.; et al. Noncovalent wild-type-sparing inhibitors of EGFR T790M. Cancer Discov. 2013, 3, 168–181. [CrossRef] [PubMed]

16. Chuang, J.C.; Salahudeen, A.A.; Wakelee, H.A. Rociletinib, a third generation EGFR tyrosine kinase inhibitor: Current data and future directions. Expert Opin. Pharmacother. 2016, 17, 989–993. [CrossRef] [PubMed]

17. Cross, D.A.; Ashton, S.E.; Ghiorghiu, S.; Eberlein, C.; Nebhan, C.A.; Spitzler, P.J.; Orme, J.P.; Finlay, M.R.; Ward, R.A.; Mellor, M.J.; et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014, 4, 1046–1061. [CrossRef] [PubMed]

18. Ward, R.A.; Anderton, M.J.; Ashton, S.; Bethel, P.A.; Box, M.; Butterworth, S.; Colclough, N.; Chorley, C.G.; Chuaqui, C.; Cross, D.A.; et al. Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). J. Med. Chem. 2013, 56, 7025–7048. [CrossRef] [PubMed]

19. Janne, P.A.; Yang, J.C.; Kim, D.W.; Planchar, D.; Ohe, Y.; Ramalingam, S.S.; Ahn, M.J.; Kim, S.W.; Su, W.C.; Horn, L.; et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 2015, 372, 1689–1699. [CrossRef] [PubMed]

20. Kim, T.M.; Song, A.; Kim, D.W.; Kim, S.; Ahn, Y.O.; Keam, B.; Jeon, Y.K.; Lee, S.H.; Chung, D.H.; Heo, D.S. Mechanisms of acquired resistance to AZD9291: A mutation-selective, irreversible EGFR inhibitor. J. Thorac. Oncol. 2015, 10, 1736–1744. [CrossRef] [PubMed]

21. Appleman, L.J. MET signaling pathway: A rational target for cancer therapy. J. Clin. Oncol. 2011, 29, 4837–4838. [CrossRef] [PubMed]

22. Engelman, J.A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J.O.; Lindeman, N.; Gale, C.M.; Zhao, X.; Christensen, J.; et al. MET amplification leads to gefitinib resistance in lung cancer by activating ErbB3 signaling. Science 2007, 316, 1039–1043. [CrossRef] [PubMed]

23. Scagliotti, G.V.; Novello, S.; Schiller, J.H.; Hirsh, V.; Sequist, L.V.; Soria, J.C.; von Pawel, J.; Schwartz, B.; von Roemeling, R.; Sandler, A.B. Rationale and design of MARQUEE: A phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin. Lung Cancer 2012, 13, 391–395. [CrossRef] [PubMed]

24. Katayama, R.; Aoyama, A.; Yamori, T.; Qi, J.; Oh-hara, T.; Song, Y.; Engelman, J.A.; Fujita, N. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res. 2013, 73, 3087–3096. [CrossRef] [PubMed]

25. Jin, H.; Yang, R.; Zheng, Z.; Romero, M.; Ross, J.; Bou-Reslan, H.; Carano, R.A.; Kasman, I.; Mai, E.; Young, J.; et al. MetMAb, the one-armed 5D5 anti-c-MET antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 2008, 68, 4360–4368. [CrossRef] [PubMed]

26. Spigel, D.; Edelman, M.; O’Byrne, K.; Paz-Ares, L.; Shames, D.; Yu, W.; Paton, V.; Mok, T. Onartuzumab Plus Erlotinib versus Erlotinib in Previously Treated Stage IIIb or IV NSCLC: Results from the Pivotal Phase III Randomized, Multicenter, Placebo-Controlled METLung (OAM49-71g) Global Trial. In Proceedings of the 2014 American Society of Clinical Oncology Annual Meeting, Chicago, IL, USA, 30 May–3 June 2014; No. 15.

27. Peled, N.; Wynes, M.W.; Ikeda, N.; Ohira, T.; Yoshida, K.; Qian, J.; Iouze, M.; Brenner, R.; Kato, Y.; Mascaux, C.; et al. Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small-cell lung cancer. Cell. Oncol. 2013, 36, 277–288. [CrossRef] [PubMed]

28. Morgillo, F.; Woo, J.K.; Kim, E.S.; Hong, W.K.; Lee, H.Y. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res. 2006, 66, 10100–10111. [CrossRef] [PubMed]

29. Choi, Y.J.; Rho, J.K.; Jeon, B.S.; Choi, S.J.; Park, S.C.; Lee, S.S.; Kim, H.R.; Kim, C.H.; Lee, J.C. Combined inhibition of IGF/FR enhances the effects of gefitinib in H1650: A lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors. Cancer Chemother. Pharmacol. 2010, 66, 381–388. [CrossRef] [PubMed]
30. Wong, K.K.; Engelman, J.A.; Cantley, L.C. Targeting the PI3K signaling pathway in cancer. Cancer Res. 2005, 65, 1642–1646. [CrossRef] [PubMed]

31. Shigematsu, H.; Takahashi, T.; Nomura, M.; Majmudar, K.; Suzuki, M.; Lee, H.; Vistuba, L.I.; Fong, K.M.; Toyooka, S.; Shimizu, N.; et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005, 65, 1540–1555. [CrossRef] [PubMed]

32. Wang, S.E.; Narasanna, A.; Perez-Torres, M.; Xiang, B.; Wu, F.Y.; Yang, S.; Carpenter, G.; Gazdar, A.F.; Muthuswamy, S.K.; Arteaga, C.L. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006, 10, 25–38. [CrossRef] [PubMed]

33. Takezawa, K.; Pirazzoli, V.; Arcila, M.E.; Nebhan, C.A.; Song, X.; de Stanchina, E.; Ohashi, K.; Janjigian, Y.Y.; Spitzler, P.J.; Melnick, M.A.; et al. HER2 amplification: A potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR790M mutation. Cancer Discov. 2012, 2, 922–933. [CrossRef] [PubMed]

34. Cappuzzo, F.; Bemis, L.; Varella-Garcia, M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N. Engl. J. Med. 2006, 354, 2619–2621. [CrossRef] [PubMed]

35. Wong, K.K.; Engelman, J.A.; Cantley, L.C. Targeting the PI3K signaling pathway in cancer. Curr. Opin. Genet. Dev. 2010, 20, 87–90. [CrossRef] [PubMed]

36. Xu, B.; Lee, K.K.; Zhang, L.; Gerton, J.L. Stimulation of mTORC1 with -leucine rescues defects associated with Roberts syndrome. PLoS Genet. 2013, 9, e1003857. [CrossRef] [PubMed]

37. Xu, B.; Gogol, M.; Gaudenz, K.; Gerton, J.L. Improved transcription and translation with -leucine stimulation of mTORC1 in Roberts syndrome. BMC Genom. 2016, 5, 17–25. [CrossRef] [PubMed]

38. Xu, B.; Sowa, N.; Cardenas, M.E.; Gerton, J.L. -leucine partially rescues translational and developmental defects associated with zebrafish models of Cornelia de Lange syndrome. Hum. Mol. Genet. 2015, 24, 1540–1555. [CrossRef] [PubMed]

39. Sos, M.L.; Koker, M.; Wein, B.A.; Heynck, S.; Rabinovsky, R.; Zander, T.; Seeger, J.M.; Weiss, J.; Fischer, F.; Frommolt, P.; et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009, 69, 3256–3261. [CrossRef] [PubMed]

40. Engelman, J.A.; Mukohara, T.; Zejnullahu, K.; Lifshits, E.; Borras, A.M.; Gale, C.M.; Naumov, G.N.; Yeap, B.Y.; Jarrell, E.; Sun, J.; et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J. Clin. Investig. 2006, 116, 2695–2706. [CrossRef] [PubMed]

41. Sequist, L.V.; Waltman, B.A.; Dias-Santagata, D.; Digumarthy, S.; Turke, A.B.; Fidias, P.; Bergethon, K.; Shaw, A.T.; Gettinger, S.; Cosper, A.K.; et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 2011, 3, 75ra26. [CrossRef] [PubMed]

42. Gadgeel, S.M.; Wozniak, A. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Clin. Lung Cancer 2013, 14, 322–332. [CrossRef] [PubMed]

43. Morinaga, R.; Okamoto, I.; Furuta, K.; Kawano, Y.; Sekijima, M.; Dote, K.; Satou, T.; Nishio, K.; Fukuoka, M.; Nakagawa, K. Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. Lung Cancer 2007, 58, 411–413. [CrossRef] [PubMed]

44. Witta, S.E.; Jotte, R.M.; Konduri, K.; Neubauer, M.A.; Spira, A.I.; Ruxer, R.L.; Varella-Garcia, M.; Bunn, P.A., Jr.; Hirsch, F.R. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J. Clin. Oncol. 2012, 30, 2248–2255. [CrossRef] [PubMed]

45. Yauch, R.L.; Januario, T.; Eberhard, D.A.; Cavet, G.; Zhu, W.; Fu, L.; Pham, T.Q.; Soriano, R.; Stinson, J.; Seshagiri, S.; et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin. Cancer Res. 2005, 11, 8866–8869. [CrossRef] [PubMed]

46. Thomson, S.; Buck, E.; Petti, F.; Griffin, G.; Brown, E.; Ramnarine, N.; Iwata, K.K.; Gibson, N.; Haley, J.D. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2005, 65, 9455–9462. [CrossRef] [PubMed]
47. Choi, Y.L.; Soda, M.; Yamashita, Y.; Ueno, T.; Takashima, J.; Nakajima, T.; Yatabe, Y.; Takeuchi, K.; Hamada, T.; Haruta, H.; et al. EML4–ALK mutations in lung cancer that confer resistance to ALK inhibitors. *N. Engl. J. Med.* 2010, 363, 1734–1739. [CrossRef] [PubMed]

48. Doebele, R.C.; Pilling, A.B.; Aisner, D.L.; Kutateladze, T.G.; Le, A.T.; Weichhardt, A.J.; Kondo, K.L.; Linderman, D.J.; Heasley, L.E.; Franklin, W.A.; et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. *Clin. Cancer Res.* 2012, 18, 1472–1482. [CrossRef] [PubMed]

49. Sasaki, T.; Koivunen, J.; Ogino, A.; Yanagita, M.; Nikiforow, S.; Zheng, W.; Lathan, C.; Marcoux, J.P.; Du, J.; Okuda, K.; et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. *Cancer Res.* 2011, 71, 6051–6060. [CrossRef] [PubMed]

50. Katayama, R.; Shaw, A.T.; Khan, T.M.; Mino-Kenudson, M.; Solomon, B.J.; Halmos, B.; Jessop, N.A.; Wain, J.C.; Yeo, A.T.; Benes, C.; et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. *Sci. Transl. Med.* 2012, 4, 120ra17. [CrossRef] [PubMed]

51. Awad, M.M.; Katayama, R.; McTigue, M.; Liu, W.; Deng, Y.L.; Brooun, A.; Friboulet, L.; Huang, D.; Falk, M.D.; Timofeevski, S.; et al. Acquired resistance to crizotinib from a mutation in *CD74*–ROSI. *N. Engl. J. Med.* 2013, 368, 2395–2401. [CrossRef] [PubMed]

52. Sasaki, T.; Rodig, S.J.; Chirieac, L.R.; Janne, P.A. The biology and treatment of EML4–ALK non-small cell lung cancer. *Eur. J. Cancer* 2010, 46, 1773–1780. [CrossRef] [PubMed]

53. Togashi, Y.; Soda, M.; Sakata, S.; Sugawara, E.; Hatano, S.; Asaka, R.; Nakajima, T.; Mano, H.; Takeuchi, K. KLC1-ALK: A novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. *PLoS ONE* 2012, 7, e31323. [CrossRef] [PubMed]

54. Boland, J.M.; Jang, J.S.; Li, J.; Lee, A.M.; Wampfler, J.A.; Erickson-Johnson, M.R.; Soares, I.; Yang, P.; Jen, J.; Oliveira, A.M.; et al. MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: Molecular analysis of 25 ALK-positive cases. *J. Thorac. Oncol.* 2013, 8, 574–581. [CrossRef] [PubMed]

55. Esfahani, K.; Agulnik, J.S.; Cohen, V. A systemic review of resistance mechanisms and ongoing clinical trials in ALK-rearranged non-small cell lung cancer. *Front. Oncol.* 2014, 4, 174. [CrossRef] [PubMed]

56. Tanizaki, J.; Okamoto, I.; Okabe, T.; Sakai, K.; Tanaka, K.; Hayashi, H.; Kaneda, H.; Takezawa, K.; Kuwata, K.; Yamaguchi, H.; et al. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4–ALK-positive non-small cell lung cancer. *Clin. Cancer Res.* 2012, 18, 6219–6226. [CrossRef] [PubMed]

57. Ji, C.; Zhang, L.; Cheng, Y.; Patel, R.; Wu, H.; Zhang, Y.; Wang, M.; Ji, S.; Belani, C.P.; Yang, J.M.; et al. Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer. *Cancer Biol. Ther.* 2014, 15, 570–577. [CrossRef] [PubMed]

58. Salgia, R. Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. *Expert Rev. Mol. Diagn.* 2016, 16, 737–749. [CrossRef] [PubMed]

59. Lee, J.Y.; Qing, X.; Xiumin, W.; Yali, B.; Chi, S.; Bak, S.H.; Hu, Y.; Sun, J.M.; Hong, J.; Oliveira, A.M.; et al. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean lung cancer consortium (KLCC-12-02). *Oncotarget* 2016, 7, 6984–6993. [PubMed]

60. Sueoka-Aragane, N.; Katakami, N.; Satouchi, M.; Yokota, S.; Aoe, K.; Iwanaga, K.; Otsuka, K.; Morita, S.; Kimura, S.; Negoro, S.; et al. Monitoring EGFR T790M with Plasma DNA from lung cancer patients in a prospective observational study. *Cancer Sci.* 2016, 107, 162–167. [CrossRef] [PubMed]

61. Seki, Y.; Fujitama, Y.; Kohno, T.; Taiaki, E.; Sunami, K.; Goto, H.; Horinouchi, K.; Kanda, S.; Nokihara, H.; Watanabe, S.; et al. Picoliter-droplet digital polymerase chain reaction-based analysis of cell-free plasma DNA to assess EGFR mutations in lung adenocarcinoma that confer resistance to tyrosine-kinase inhibitors. *Oncologist* 2016, 21, 156–164. [CrossRef] [PubMed]

62. Ishii, H.; Azuma, K.; Sakai, K.; Kawahara, A.; Yamada, K.; Tokito, T.; Okamoto, I.; Nishio, K.; Hoshino, T. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples. *Oncotarget* 2015, 6, 30850–30858. [PubMed]
64. Wang, Z.; Chen, R.; Wang, S.; Zhong, J.; Wu, M.; Zhao, J.; Duan, J.; Zhuo, M.; An, T.; Wang, Y.; et al. Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC. *PLoS ONE* 2014, 9, e107800. [CrossRef] [PubMed]

65. Zheng, D.; Ye, X.; Zhang, M.Z.; Sun, Y.; Wang, J.Y.; Ni, J.; Zhang, H.P.; Zhang, L.; Luo, J.; Zhang, J.; et al. Plasma *EGFR* T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. *Sci. Rep.* 2016, 6, 20913. [CrossRef] [PubMed]

66. Sakai, K.; Horiike, A.; Irwin, D.L.; Kudo, K.; Fujita, Y.; Tanimoto, A.; Sakatani, T.; Saito, R.; Kaburaki, K.; Yanagitani, N.; et al. Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor. *Cancer Sci.* 2013, 104, 1198–1204. [CrossRef] [PubMed]

67. Mundaresan, T.K.; Sequist, L.V.; Heymach, J.V.; Riely, G.J.; Janne, P.A.; Koch, W.H.; Sullivan, J.P.; Fox, D.B.; Maher, R.; Muzikansky, A.; et al. Detection of T790M, the acquired resistance *EGFR* mutation, by tumor biopsy versus noninvasive blood-based analyses. *Clin. Cancer Res.* 2016, 22, 1103–1110. [CrossRef] [PubMed]

68. Marcq, M.; Vallee, A.; Bizieux, A.; Denis, M.G. Detection of *EGFR* mutations in the plasma of patients with lung adenocarcinoma for real-time monitoring of therapeutic response to tyrosine kinase inhibitors? *J. Thorac. Oncol.* 2014, 9, e49–e50. [CrossRef] [PubMed]

69. Del Re, M.; Tiseo, M.; Bordi, P.; D’Incecco, A.; Camerini, A.; Petriani, I.; Lucchesi, M.; Inno, A.; Spada, D.; Vasile, E.; et al. Contribution of KRAS mutations and c.2369C > T (p.T790M) *EGFR* to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: A study on circulating tumor DNA. *Oncotarget* 2016. [CrossRef]

70. Oxnard, G.R.; Arcila, M.E.; Chmielecki, J.; Ladanyi, M.; Miller, V.A.; Pao, W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. *Clin. Cancer Res.* 2011, 17, 5530–5537. [CrossRef] [PubMed]

71. Karpovich, C.; Goldman, J.W.; Sun, J.M.; Mann, E.; Sequist, L.V.; Konopa, K.; Wen, W.; Angenendt, P.; Horn, L.; Spigel, D.; et al. Assessment of *EGFR* mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib (CO-1686). *Clin. Cancer Res.* 2016, 22, 2386–2395. [CrossRef] [PubMed]

72. Thress, K.S.; Paweletz, C.P.; Felip, E.; Cho, B.C.; Stetson, D.; Dougherty, B.; Lai, Z.; Markovets, A.; Vivancos, A.; Kuang, Y.; et al. Acquired *EGFR* C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring *EGFR* T790M. *Nat. Med.* 2015, 21, 560–562. [CrossRef] [PubMed]

73. Marchetti, A.; Palma, J.F.; Felicioni, L.; de Pas, T.M.; Chiari, R.; Del Grammastro, M.; Filice, G.; Ludovini, V.; Brandes, A.A.; Chella, A.; et al. Early prediction of response to tyrosine kinase inhibitors by quantification of *EGFR* mutations in plasma of NSCLC patients. *J. Thorac. Oncol.* 2015, 10, 1437–1443. [CrossRef] [PubMed]

74. Tseng, J.S.; Yang, T.Y.; Tsai, C.R.; Chen, K.C.; Hsu, K.H.; Tsai, M.H.; Yu, S.L.; Su, K.Y.; Chen, J.J.; Chang, G.C. Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: Are there features to guide patient selection? *Int. J. Mol. Sci.* 2014, 15, 68–73. [CrossRef] [PubMed]

75. Imamura, F.; Uchida, J.; Kukita, Y.; Kumagai, T.; Nishino, K.; Inoue, T.; Kimura, M.; Oba, S.; Kato, K. Prospective molecular marker analyses of *EGFR* and *KRAS* features to guide patient selection? *J. Thorac. Oncol.* 2015, 10, 603–610. [CrossRef] [PubMed]

76. Reck, M.; Sellers, M.V.; et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer. *J. Clin. Oncol.* 2011, 29, 4113–4120. [CrossRef] [PubMed]

77. Douillard, J.Y.; Shepherd, F.A.; Hirsh, V.; Mok, T.; Socinski, M.A.; Gervais, R.; Liao, M.L.; Bischoff, H.; Reck, M.; Sellers, M.V.; et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. *J. Clin. Oncol.* 2011, 29, 744–752. [CrossRef] [PubMed]

78. Ulivi, P.; Delmonte, A.; Chiadini, E.; Calistri, D.; Papi, M.; Mariotti, M.; Verlicchi, A.; Ragazzini, A.; Capelli, L.; Gamboni, A.; et al. Gene mutation analysis in *EGFR* wild type NSCLC responsive to erlotinib: Are there features to guide patient selection? *Int. J. Mol. Sci.* 2014, 16, 747–757. [CrossRef] [PubMed]

79. Zhu, C.Q.; da Cunha Santos, G.; Ding, K.; Sakurada, A.; Cutz, J.C.; Liu, N.; Zhang, T.; Marrano, P.; Whitehead, M.; Squire, J.A.; et al. Role of KRAS and *EGFR* as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. *J. Clin. Oncol.* 2008, 26, 4268–4275. [CrossRef] [PubMed]
80. Schneider, C.P.; Heigener, D.; Schott-von-Romer, K.; Gutz, S.; Laack, E.; Digel, W.; Guschall, W.R.; Franke, A.; Bodenstein, H.; Schmidtgen, C.; et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: An analysis of patients from German centers in the TRUST study. *J. Thorac. Oncol.* 2008, 3, 1446–1453. [CrossRef] [PubMed]

81. Ilie, M.; Long, E.; Butori, C.; Hofman, V.; Coelle, C.; Mauro, V.; Zahaf, K.; Marquette, C.H.; Mouroux, J.; Paterlini-Brechot, P.; et al. ALK-gene rearrangement: A comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. *Ann. Oncol.* 2012, 23, 2907–2913. [CrossRef] [PubMed]

82. Pailler, E.; Adam, J.; Barthelemy, A.; Oulhen, M.; Auger, N.; Valent, A.; Borget, I.; Planchard, D.; Taylor, M.; Andre, F.; et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. *J. Clin. Oncol.* 2013, 31, 2273–2281. [CrossRef] [PubMed]

83. He, W.; Xu, D.; Wang, Z.; Xiang, X.; Tang, B.; Li, S.; Hou, M.; Zhang, Y.; Chen, J.F.; Lin, M.; et al. Detecting ALK-rearrangement of CTC enriched by nanovelcro chip in advanced NSCLC patients. *Oncotarget* 2016. [CrossRef]

84. Tan, C.L.; Lim, T.H.; Lim, T.K.; Tan, D.S.; Chua, Y.W.; Ang, M.K.; Pang, B.; Lim, C.T.; Takano, A.; Lim, A.S.; et al. Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer. *Oncotarget* 2016. [CrossRef] [PubMed]

85. Nilsson, R.J.; Karachaliou, N.; Berenguer, J.; Gimenez-Capitan, A.; Schellen, P.; Teixido, C.; Tannous, J.; Kuiper, J.L.; Drees, E.; Grabowska, M.; et al. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. *Oncotarget* 2016, 7, 1066–1075. [CrossRef] [PubMed]

© 2016 by the author; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).